SPRO
Spero Therapeutics Inc
1.20$
+0.8%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +188.6% | -94.3% | +142.6% | +32.1% | +11.7% | -61.0% | +100.9% | -74.2% | +1,201.1% | -99.3% | -100.0% | – | |
| – | +7,886.1% | -110.2% | – | -100.0% | +4,731,600.0% | -85.6% | – | – | – | – | – | – | |
| – | -3.1% | -82.5% | -421.8% | – | -690.9% | – | – | -74.2% | +1,201.1% | -99.3% | – | – | |
| – | +1.0% | +4.7% | +36.9% | +13.2% | +7.3% | -52.8% | -21.6% | -19.4% | -35.0% | -48.0% | +18.0% | – | |
| – | +2.8% | +0.9% | -6.5% | -6.1% | +20.5% | +8.9% | -13.9% | -29.0% | +3.0% | +13.7% | +32.8% | – | |
| – | -198.7% | – | -69.6% | +479.5% | -280.5% | – | +103.5% | -23.0% | -24.7% | -5.5% | +27.3% | – | |
| – | – | -127.7% | – | – | – | – | – | – | – | -124.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -124.6% | – | – | – | – | – | – | – | -122.7% | – | – | |
| – | -82.5% | -123.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | -124.7% | – | – | – | – | – | – | – | -122.9% | – | – | |
| – | +1,383.2% | -124.5% | – | – | – | – | – | – | – | -122.7% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.